Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jurgen B Bulitta

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Pharmaceutical Research|June 15, 2012
Powder strength distributions for understanding de-agglomeration of lactose powdersShyamal C Das, Srinivas Ravindra Babu Behara, Jurgen B Bulitta, et al.
The AAPS Journal|May 1, 2008
Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailabilityHo-Leung Fung, Pei-Suen Tsou, Jurgen B Bulitta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the deadBrian T Tsuji, Olanrewaju O Okusanya, Jurgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|August 22, 2012
Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profileCornelia B Landersdorfer, Jurgen B Bulitta, Carl M J Kirkpatrick, et al.
Chemotherapy|October 26, 2011
Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combinationJurgen B Bulitta, Martina Kinzig, Christoph K Naber, et al.
Pharmacotherapy|December 1, 2010
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingLauren M Lim, Neang Ly, Dana Anderson, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2015
Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutatorsZackery P Bulman, Mark D Sutton, Neang S Ly, et al.
The Journal of Antimicrobial Chemotherapy|June 12, 2012
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutationsBrian T Tsuji, Jurgen B Bulitta, Tanya Brown, et al.
Scientific Reports|May 20, 2016
Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage RegimensSoon-Ee Cheah, Matthew D Johnson, Yan Zhu, et al.
International Journal of Antimicrobial Agents|October 25, 2016
Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumanniiJustin R Lenhard, Jonathan S Gall, Jurgen B Bulitta, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Pharmaceutical Research|June 15, 2012
Powder strength distributions for understanding de-agglomeration of lactose powdersShyamal C Das, Srinivas Ravindra Babu Behara, Jurgen B Bulitta, et al.
The AAPS Journal|May 1, 2008
Pharmacokinetics of 1,4-butanediol in rats: bioactivation to gamma-hydroxybutyric acid, interaction with ethanol, and oral bioavailabilityHo-Leung Fung, Pei-Suen Tsou, Jurgen B Bulitta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 7, 2011
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the deadBrian T Tsuji, Olanrewaju O Okusanya, Jurgen B Bulitta, et al.
Antimicrobial Agents and Chemotherapy|August 22, 2012
Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profileCornelia B Landersdorfer, Jurgen B Bulitta, Carl M J Kirkpatrick, et al.
Chemotherapy|October 26, 2011
Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combinationJurgen B Bulitta, Martina Kinzig, Christoph K Naber, et al.
Pharmacotherapy|December 1, 2010
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosingLauren M Lim, Neang Ly, Dana Anderson, et al.
Antimicrobial Agents and Chemotherapy|April 29, 2015
Emergence of polymyxin B resistance influences pathogenicity in Pseudomonas aeruginosa mutatorsZackery P Bulman, Mark D Sutton, Neang S Ly, et al.
The Journal of Antimicrobial Chemotherapy|June 12, 2012
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutationsBrian T Tsuji, Jurgen B Bulitta, Tanya Brown, et al.
Scientific Reports|May 20, 2016
Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage RegimensSoon-Ee Cheah, Matthew D Johnson, Yan Zhu, et al.
International Journal of Antimicrobial Agents|October 25, 2016
Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumanniiJustin R Lenhard, Jonathan S Gall, Jurgen B Bulitta, et al.
Pageof 3